Nabil Dib, MD
Interventional Cardiology · Gilbert, AZNPI 1508867383
Payments from drug & device makers
Across 550 payments — averaging $3993.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$472K
- Janssen Research & Development, LLC$375K
- Merck$267K
- CSL Behring$266K
- Eli Lilly$229K
- Medical Device Business Services, Inc.$212K
- plus $376K from 27 others
Across 1 payment — averaging $1188.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Speaking & faculty fees$10,20056%
- Grants$660%
- Travel & lodging$5,13528%
- Food & beverage$2,69315%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $471,697 |
| Janssen Research & Development, LLC | 89 | $375,074 |
| Merck | 15 | $267,142 |
| CSL Behring | 156 | $266,364 |
| Eli Lilly | 15 | $228,553 |
| Medical Device Business Services, Inc. | 68 | $211,636 |
| Abbott | 49 | $75,706 |
| Astrazeneca AB | 1 | $69,533 |
| Alnylam Pharmaceuticals Inc. | 17 | $52,841 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $45,543 |
| Boehringer Ingelheim International GmbH | 8 | $44,465 |
| Amgen | 17 | $39,983 |
| Array Biopharma Inc | 20 | $31,166 |
| AstraZeneca | 15 | $10,433 |
| Medtronic(2 entities) | 16 | $4,728 |
| Heartflow, Inc. | 1 | $250 |
| Abiomed | 6 | $227 |
| Biosense Webster, Inc. | 2 | $159 |
| Asahi Intecc USA, Inc. | 1 | $122 |
| Angiodynamics, Inc. | 1 | $103 |
| Cardiac Dimensions, Inc. | 1 | $97 |
| Pfizer | 4 | $71 |
| Boehringer Ingelheim | 3 | $65 |
| Kestra Medical Technology Services, Inc. | 3 | $56 |
| Mimedx Group, Inc. | 1 | $46 |
| Johnson & Johnson | 3 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Edwards Lifesciences | 1 | $24 |
| W. L. Gore & Associates, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$10,315
- Resolute$4,222
- FFRct$250
- RESOLUTE ONYX$164
- Impella$128
- Soundstar$125
- Asahi Peripheral Vascular Wires$122
- Auryon Laser System 100-120 Vac$103
How this compares
$2,196,262 in reported general payments places this provider in the 95th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 14 | $16,594 |
| EliquisApixaban | 27 | $14,996 |
| Metoprolol Succinate | 39 | $551 |
| Atorvastatin Calcium | 35 | $442 |
| Ezetimibe | 13 | $337 |
| Amlodipine Besylate | 33 | $203 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 20 | $189 |
| ClopidogrelClopidogrel Bisulfate | 18 | $179 |
| Losartan Potassium | 19 | $108 |
| Lisinopril | 13 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $471,697 | $16,59414 claims |
| PfizerEliquis | $71 | $14,99627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Gilbert
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
- Timothy ByrnePhoenix$2.1M
- Ashish PershadChandler$1.4M
- Mohamad LazkaniPhoenix$1.1M
- Parminder SinghPhoenix$854K
- Samuel ButmanCottonwood$706K
- Ajay TuliTucson$705K
- Akil LoliPhoenix$506K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.